SEC Filing Summary: Aadi Bioscience, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. on November 8, 2023. The report serves to announce the company's financial results for the quarter ended September 30, 2023. The full details of these results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not explicitly stated within the body of this 8-K document.
Material Changes
No material changes versus the prior comparable period are described in the text of this filing. The document solely acts as a notification that the quarterly results have been issued.
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It includes a standard disclaimer stating that the information furnished in Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q3 2023 financial figures.
- Verify the company's cash position and burn rate from the full press release, as this 8-K does not list liquidity details.
- Confirm any updated clinical trial milestones or operational guidance mentioned in the referenced press release.